GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Net Margin %

Theravance Biopharma (FRA:0TB) Net Margin % : -48.45% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Theravance Biopharma's Net Income for the three months ended in Dec. 2023 was €-7.80 Mil. Theravance Biopharma's Revenue for the three months ended in Dec. 2023 was €16.11 Mil. Therefore, Theravance Biopharma's net margin for the quarter that ended in Dec. 2023 was -48.45%.

The historical rank and industry rank for Theravance Biopharma's Net Margin % or its related term are showing as below:

FRA:0TB' s Net Margin % Range Over the Past 10 Years
Min: -2028.05   Med: -373.73   Max: 1698.54
Current: -72.78


FRA:0TB's Net Margin % is ranked better than
58.08% of 1033 companies
in the Biotechnology industry
Industry Median: -162.58 vs FRA:0TB: -72.78

Theravance Biopharma Net Margin % Historical Data

The historical data trend for Theravance Biopharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Net Margin % Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -322.08 -386.91 -360.56 1,698.53 -96.11

Theravance Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -212.05 -113.79 -57.03 -48.45 -80.42

Competitive Comparison of Theravance Biopharma's Net Margin %

For the Biotechnology subindustry, Theravance Biopharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Net Margin % falls into.



Theravance Biopharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Theravance Biopharma's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-50.612/52.658
=-96.11 %

Theravance Biopharma's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-7.804/16.107
=-48.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theravance Biopharma  (FRA:0TB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Theravance Biopharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma (FRA:0TB) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines